Market Research Logo

Novelion Therapeutics Inc (QLT) - Financial and Strategic SWOT Analysis Review

Novelion Therapeutics Inc (QLT) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Novelion Therapeutics Inc (Novelion) is a biotechnology company that focuses on the development and commercializes products and devices for the treatment of certain retinal diseases. The company's product candidate, Zuretinol is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle for the potential treatment of certain age-related and inherited retinal degenerative diseases. It is being evaluated in Phase III for the treatments of leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). Novelion marketed products include Metreleptin and Lomitapide which are marketed in the US under the brand name Myalept and Juxtapid. It operates along with its subsidiaries in the US, the UK, Japan, Canada and others. Novelion is headquartered in Vancouver, British Columbia, Canada.

Novelion Therapeutics Inc Key Recent Developments

Jun 01,2017: Novelion Therapeutics Appoints John J. Orloff, M.D., to Its Board of Directors, Steps Down as EVP, Head of R&D
May 09,2017: Novelion Therapeutics Reports First Quarter 2017 Financial Results
Apr 19,2017: Novelion Therapeutics’ Request to Voluntarily Delist from the Toronto Stock Exchange Granted
Mar 31,2017: Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors
Mar 15,2017: Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company 5
Novelion Therapeutics Inc - Key Facts 5
Novelion Therapeutics Inc - Key Employees 6
Novelion Therapeutics Inc - Key Employee Biographies 7
Novelion Therapeutics Inc - Major Products and Services 8
Novelion Therapeutics Inc - History 9
Novelion Therapeutics Inc - Company Statement 11
Novelion Therapeutics Inc - Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Section 2 – Company Analysis 18
Novelion Therapeutics Inc - Business Description 18
Novelion Therapeutics Inc - SWOT Analysis 19
SWOT Analysis - Overview 19
Novelion Therapeutics Inc - Strengths 19
Novelion Therapeutics Inc - Weaknesses 20
Novelion Therapeutics Inc - Opportunities 21
Novelion Therapeutics Inc - Threats 22
Novelion Therapeutics Inc - Key Competitors 23
Section 3 – Company Financial Ratios 24
Financial Ratios - Capital Market Ratios 24
Financial Ratios - Annual Ratios 25
Performance Chart 28
Financial Performance 28
Financial Ratios - Interim Ratios 29
Financial Ratios - Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32
Novelion Therapeutics Inc, Recent Deals Summary 33
Section 5 – Company’s Recent Developments 34
Jun 01, 2017: Novelion Therapeutics Appoints John J. Orloff, M.D., to Its Board of Directors, Steps Down as EVP, Head of R&D 34
May 09, 2017: Novelion Therapeutics Reports First Quarter 2017 Financial Results 35
Apr 19, 2017: Novelion Therapeutics’ Request to Voluntarily Delist from the Toronto Stock Exchange Granted 37
Mar 31, 2017: Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors 38
Mar 15, 2017: Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results 39
Jan 09, 2017: Novelion Therapeutics Reports Preliminary 2016 Net Product Sales and Provides 2017 Outlook 42
Nov 01, 2016: QLT Announces Third Quarter 2016 Results 43
Aug 09, 2016: QLT Announces Second Quarter 2016 Results 45
May 05, 2016: QLT Announces First Quarter 2016 Results 47
Feb 25, 2016: QLT Announces 2015 Fourth Quarter and Year End Results 49
Section 6 – Appendix 51
Methodology 51
Ratio Definitions 51
About GlobalData 55
Contact Us 55
Disclaimer 55
List of Tables
Novelion Therapeutics Inc, Key Facts 5
Novelion Therapeutics Inc, Key Employees 6
Novelion Therapeutics Inc, Key Employee Biographies 7
Novelion Therapeutics Inc, Major Products and Services 8
Novelion Therapeutics Inc, History 9
Novelion Therapeutics Inc, Subsidiaries 16
Novelion Therapeutics Inc, Key Competitors 23
Novelion Therapeutics Inc, Ratios based on current share price 24
Novelion Therapeutics Inc, Annual Ratios 25
Novelion Therapeutics Inc, Annual Ratios (Cont...1) 26
Novelion Therapeutics Inc, Annual Ratios (Cont...2) 27
Novelion Therapeutics Inc, Interim Ratios 29
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32
Novelion Therapeutics Inc, Recent Deals Summary 33
Currency Codes 51
Capital Market Ratios 51
Equity Ratios 52
Profitability Ratios 52
Cost Ratios 53
Liquidity Ratios 53
Leverage Ratios 54
Efficiency Ratios 54
List of Figures
Novelion Therapeutics Inc, Performance Chart (2012 - 2016) 28
Novelion Therapeutics Inc, Ratio Charts 30
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 32

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report